IsoRay Inc. (ISR)

IsoRay Stock Price Hammered After… Excellent Study Results post image

IsoRay, Inc. (ISR – $1.80), our favorite medical technology Company, is an innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head, neck and gynecological cancers. Its various products, including Cesium-131 seeds, sutured seeds, stranded mesh and the GliaSite radiation therapy system, give physicians the ability to directly place Read More

IsoRay Continues To Make Waves In Cancer Treatment Market post image

IsoRay, Inc. (ISR - $1.57), our favorite medical technology Company, is an innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head, neck and gynecological cancers. IsoRay is the exclusive manufacturer of Cesium-131, which allows for the precise treatment of many different cancers thanks to its unrivaled blend of Read More

96% of Patients Experience NO Recurrence of Brain Cancer After IsoRay Treatment post image

IsoRay, Inc. (ISR – $1.76), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of cancers of the prostate, brain, lung, head and neck and gynecological, announced exceptional results conducted by researchers at the Barrow Neurological Institute, one of the world’s foremost brain cancer research and treatment sites Read More

Small Cap Updates & New Recommendations – April 5, 2014 post image

This week we have updates on Enterprise Group (E), Global Minerals (CTG) and IsoRay (ISR). Enterprise Group (E - $1.02), a consolidator of construction services companies operating in the energy, utility and transportation infrastructure industries, announced strong financial results for its fiscal year 2013. Revenues for 2013 reached $34.8 million, an increase of $16.3 million Read More

IsoRay logo

IsoRay Inc’s (ISR - $2.42) stock price went through the roof this week as it announced the world's first successfully completed pediatric implant using IsoRay Medical's Cesium-131 brachytherapy mesh. We first featured IsoRay on Smallcaps Investment Research two months ago at 75 cents because we felt that a company with such a valuable technology and Read More